Meeting
2018 Palliative and Supportive Care in Oncology Symposium
A systematic review and meta- analysis of randomized controlled trials to evaluate the risk of hematological toxicities in patients with cancer treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors.
Authors
Anita Sultan
Texas Tech University Health Sciences Center, Lubbock, TX
Anita Sultan, Sriman Swarup, Myo Zaw, Myat M. Han, Yin Mon Myat, Htay Htay Aung, Myet Mon Mon Zin, Kalpana Panigrahi, Kyaw Zin Thein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Advance Care Planning; Caregiver Support; Coordination and Continuity of Care; End-of-Life Care; Models of Care; Survivorship; and Symptom Biology, Assessment and Management
Track
Advance Care Planning,End-of-Life Care,Survivorship,Coordination and Continuity of Care,Symptom Biology, Assessment, and Management,Models of Care,Caregiver Support
Sub Track
Symptom Biology, Assessment, and Management
Citation
J Clin Oncol 36, 2018 (suppl 34; abstr 217)
DOI
10.1200/JCO.2018.36.34_suppl.217
Abstract #
217
Poster Bd #
G3
Abstract Disclosures
Similar Posters
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Risk of gastrointestinal and hepatic toxicities in patients with cancer treated with poly adenosine diphosphate ribose polymerase inhibitors: A meta-analysis of seven phase III trials.
First Author: Myo Zaw
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Risk of health-related quality-of-life events and pulmonary toxicities in patients with cancer treated with poly adenosine diphosphate ribose polymerase inhibitors: A meta-analysis of seven phase III trials.
First Author: Sriman Swarup
Poster
2020 ASCO Virtual Scientific Program
Risk of secondary hematologic malignancies in patients with ovarian cancer treated with PARP inhibitors: A combined meta-analysis of seven phase III randomized controlled trials.
First Author: Thura Htut
Poster
2022 ASCO Annual Meeting
Real-world use, tolerability, and dose modifications of PARP inhibitors in ovarian cancer.
First Author: David M. O'Malley